PDAC - Pancreatic Ductal Adenocarcinoma Clinical Trial
Official title:
Defining a Vascular Phenotype of Pancreatic Ductal Adenocarcinoma With CT Perfusion Using Quantitative Radiomics
With CT-perfusion(CTP) it is possible to visualize the enhancement pattern of the tumor. The perfusion CT, interleaved with a routine contrast enhanced CT (CECT) will be performed at diagnosis in all patients (goal: n=125 patients) and at the first follow-up at 3 months in patients treated with systemic therapy (goal: n=50 patients). Also, the histopathology will be collected for resected tumors to perform histopathology analysis. CTP parameters will be correlated to immunohistological findings and clinical outcome. The main goal of the study is to create an AI-assisted method to classify patients with a vascular phenotype of pancreatic ductal adenocarcinoma (PDAC). The investigators expect that this phenotype can be used to predict overall survival and chemotherapy response.
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05642962 -
Pancrelipase in People With Pancreatic Ductal Adenocarcinoma (PDAC)
|
Phase 1/Phase 2 | |
Recruiting |
NCT06122896 -
Prospective Screening for Pancreatic Ductal Adenocarcinoma in High-Risk Individuals
|
Early Phase 1 | |
Recruiting |
NCT05262855 -
Study of [68Ga]FAPI-46 PET in Patients With Pancreatic Ductal Carcinoma
|
Phase 2 | |
Recruiting |
NCT04700488 -
Magnetic Resonance Imaging (MRI) to Predict Outcomes of Pancreatic Ductal Adenocarcinoma (PDAC)
|
N/A | |
Not yet recruiting |
NCT05947825 -
Sitagliptin Combined With Gemcitabine and Albumin-bound Paclitaxel in PDAC Patients
|
Phase 2 | |
Recruiting |
NCT06151223 -
A Prospective Registry for Patients at High-Risk for Pancreatic Cancer
|
||
Recruiting |
NCT05845801 -
Prospective Registry of Young-Adult Patients Diagnosed With Pancreatic Cancer
|
||
Recruiting |
NCT05853198 -
Circulating Tumor DNA as Surgical Biomarker in Patients With PancrEatic Adenocarcinoma for Statement of Resectability
|
N/A | |
Recruiting |
NCT05727020 -
Volatile Organic Compound Assessment in Pancreatic Ductal Adenocarcinoma
|
||
Recruiting |
NCT05218889 -
Surufatinib Plus Camrelizumab and AS in First Line Treatment of Advanced Metastatic Pancreatic Cancer
|
Phase 1/Phase 2 | |
Recruiting |
NCT05132244 -
Monitoring and Managing Glucose Levels in People With Pancreatic Cancer
|
N/A | |
Recruiting |
NCT04365049 -
Nab-Paclitaxel and Gemcitabine Plus Camrelizumab and Radiotherapy for Locally Advanced Pancreatic Adenocarcinoma
|